Bioprospecting and access-and-benefit sharing
Searching biodiversity for useful genetic resources and compounds under access permits and benefit-sharing agreements required by the Convention on Biological Diversity and the Nagoya Protocol.
1 · What it gives
Companies in pharma, cosmetics and research that use genetic resources from abroad need documented access and benefit-sharing compliance. Rules differ by provider country and by user-country implementation. The portal has a page on genomic prospecting in international waters; this page covers terrestrial resources and Nagoya compliance.
- Permit and prior informed consent: Identify the provider country and obtain access permit and prior informed consent.
- Mutually agreed terms: Negotiate benefit-sharing terms (monetary and non-monetary) with the provider.
- Collection and screening: Collect samples and screen extracts or genes for activity.
- Compliance and reporting: Keep documentation of origin and report use as required by user-country measures.
Draft from established general knowledge; not source-checked (verified: false, confidence: low).
2 · What it replaces 3 · matched by industry
| D3E2 | Biodegradable scrub particles and exfoliants instead of polyethylene microbeads Replaces: Polyethylene (and PP/PET/PMMA) microbeads in rinse-off cosmetics: face/body scrubs, toothpastes, shower gels; glitter (polyester/alu … | COSM |
| D1E– | Biosurfactant and APG cleansing — sophorolipids, rhamnolipids, alkyl polyglucosides — instead of petrochemical SLES/SLS Replaces: Petrochemical anionic surfactants (SLES/SLS) and their ethoxylated feedstock chain (1,4-dioxane contamination risk at trace levels, … | COSM |
| D1E– | Fermentation cosmetic ingredients instead of shark-liver squalene, rooster-comb hyaluronic acid and animal collagen Replaces: Shark-liver oil squalene (deep-sea shark fisheries); hyaluronic acid from rooster combs; bovine/porcine collagen extracts (and their … | COSM |
3 · How to implement 4 steps
- 1Permit and prior informed consentIdentify the provider country and obtain access permit and prior informed consent.
- 2Mutually agreed termsNegotiate benefit-sharing terms (monetary and non-monetary) with the provider.
- 3Collection and screeningCollect samples and screen extracts or genes for activity.
- 4Compliance and reportingKeep documentation of origin and report use as required by user-country measures.
4 · Who delivers
Matched suppliers (matched automatically)
| Genmab | Denmark | Producer | active |
| Himalaya Wellness | India | Producer | unverified |
| Regeneron Pharmaceuticals | United States | Producer | active |
| arGEN-X | Netherlands | Producer | active |
| Amgen | United States | Producer | active |
| AstraZeneca | United Kingdom | Producer | active |
| Bayer | Germany | Producer | active |
| Becton Dickinson | United States | Producer | active |
| Beiersdorf | Germany | Producer | active |
| Biogen | United States | Producer | active |
| Boehringer Ingelheim | Germany | Producer | active |
| China Resources Pharmaceutical | Hong Kong | Producer | unverified |
Leading companies and institutes (from the brief)
5 · Rules & route to market
declaration (SGR for some categories)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The policy corpus includes the National Bioprospecting Strategy of Kenya (2011); the gap analysis also cites Colombia and South Africa.
European Union
Unclear national rules, retroactive claims and reputational risk from biopiracy allegations are the usual risks to check.
Sources:
- IACGB Global Policy Report 2026 (appendix)
China
No companies are linked yet; the portal’s supplier matching adds them under the related industries.
6 · Money: tenders & grants
| Grant | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States | Oct 15, 2027 364 days |
| Grant | NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) National Institutes of Health · United States | Jul 5, 2029 993 days |
7 · Tech stack & innovations
Where this appears 4 sources
Appears in 4 distinct sources across 3 regions, 2014–2024.
- policy documents 4
Regions: Colombia · Kenya · South Africa
- 2021: 0
- 2022: 0
- 2023: 0
- 2024: 11
- 2025: 0
- 2026: 0
- 2027: 0
Matched themes 1
Bioprospecting
Themes from forum programmes, policy documents and reports are mapped to technologies automatically and then reviewed; counts are distinct sources, not mentions, and are not a ranking. data sources and method → · Trending, not yet covered →
Sources 3 · 0 independent · 3 producer sites
Producers' own sites 3
- Iacgb global policy report 2026 (appendix) producer checked 2026-11-04 · link not kept
- www.cbd.int producer checked 2026-11-05
- www.informea.org producer checked 2026-11-05